1043-45 Preprocedural statin administration and incidence of creatine-kinase and troponin I elevation after elective percutaneous coronary stent implantation  by Briguori, Carlo et al.
42A ABSTRACTS - Angiography & Interventional Cardiology JACC March 3, 2004
An
gi
og
ra
ph
y 
&
 In
te
rv
en
tio
na
l C
ar
di
ol
og
y
1043-43 The Incremental Hospital Cost of Treating Major 
Complications Among Medicare Beneficiaries 
Undergoing Percutaneous Coronary Interventions
Aaron Kugelmass, David Cohen, Phillip Brown, Michael Mack, Edmund Becker, Steven 
Culler, April Simon, Emory University, Atlanta, GA, Cardiac Data Solutions, Inc., Atlanta, 
GA
Background: Studies of Percutaneous Coronary Intervention (PCI) have focused on
mortality and restenosis. Little is known about the hospital cost of treating acute PCI
complications. We studied the incremental hospital resource consumption (cost and
length of stay (LOS)) due to acute PCI complications.
Methods: A retrospective analysis was conducted using the Medicare Provider Analysis
and Review (MedPar) Files from 2002. This consists of 313,517 admissions whose pri-
mary procedure was PCI. Procedures, complications, and comorbidities were identified
using ICD-9 codes. Hospital costs were estimated from billed charges using the hospi-
tal’s cost-to charge ratio. Multivariate regression analysis was used to estimate the incre-
mental hospital resources associated with complications, after controlling for age,
gender, and 26 comorbiditites.
Results: Complications of PCI procedures occur in less than 3.3% of admissions. The
hospital cost (unadjusted for morbidities) of PCI with at least one major complication was
$29,440 (mean LOS of 9.4 days) compared to $14,046 (mean LOS 2.9 days) for those
without a complication. The table reports estimated incremental cost and LOS after con-
trol for age, gender, and comorbidities.
Conclusion: This retrospective study of Medicare beneficiaries indicates that complica-
tions significantly increase cost. Quality improvement efforts to reduce complications,
could not only result in improved patient outcomes, but could also prove to be cost-effec-
tive.
1043-44 Identifying Patients at Risk for Ischemia-Driven Target 
Vessel Revascularization After Primary Percutaneous 
Coronary Intervention: Lessons From the Primary 
Angioplasty in Myocardial Infarction (PAMI) Trials
Rajendra H. Mehta, Kishore J. Harjai, Judy Boura, William O'Neill, Cindy L. Grines, On 
Behalf of Primary Angioplasty in Myocardial Infarction (PAMI) Investigators, University of 
Michigan, Ann Arbor, MI, William Beaumont Hospital, Royal Oak, MI
Background: Patients (pts) undergoing primary percutaneous coronary intervention
(PCI) may require target vessel revascularization for recurrent ischemic event. However,
there is no data regarding pts at risk for ischemia-driven target vessel revascularization
(ITVR).
Methods: We examined 2981 pts with ST elevation myocardial infarction enrolled in vari-
ous PAMI trials, who underwent primary PCI. Univariate testing followed by multivariate
logistic regression analysis was performed to determine pt characteristics that identified
those at risk for ITVR.
Results: Of 2981 pts undergoing primary PCI, ITVR was required in 321 pts (11%) at
six-months. A third of ITVR (107/321) were required before hospital discharge. Com-
pared to the cohort without ITVR, pts requiring ITVR were younger (61+12 vs. 59+12,
p=0.036), females (26% vs. 32%, p=0.018), more likely to have systolic blood pressure
>100 mmHg on presentation (67% vs. 74%, p=0.022), Killip Class I on presentation (87%
vs. 91%, p=0.05), family history of coronary artery disease (36% vs. 42%, p=0.035), and
higher post-procedure dissection (15% vs. 23%, p=0.001) and in-hospital (1% vs. 10%,
p<0.001) and six-month (2% vs. 19%) reinfarction. In contrast, left circumflex as infarct
artery (15% vs. 10%, p=0.022), and the use of ticlopidine (78% vs. 72%, p=0.044) and
stents (41% vs. 35%, p=0.057) were less frequent among pts requiring ITVR. Multivariate
analysis identified age (for each 10 years increment, odds ratio [OR], 0.85; 95% confi-
dence interval [CI], 0.76-0.94; p=0.003), female gender (OR 1.41, 95% CI, 1.05-1.89;
p=0.022), and final dissection (OR 1.69, 95% CI, 1.23-2.33, p=0.001) as independent
risk factors for ITVR (c statistic 0.57, DF 8, p=0.14). In-hospital and six-month mortality
were similar in the 2 groups while length of stay was longer in the pts requiring ITVR
(median 6.3+5.4 vs. 7.3+5.7 days, p<0.001).
Conclusions: Our study identifies the incidence, risk factors and outcomes for pts who
require ITVR after primary PCI. Importantly, our data suggests that no increase in
adverse events occurs, if ITVR is promptly performed to treat recurrent ischemia in
patients undergoing primary PCI.
1043-45 Preprocedural Statin Administration and Incidence of 
Creatine-Kinase and Troponin I Elevation After Elective 
Percutaneous Coronary Stent Implantation
Carlo Briguori, Antonio Colombo, Amelia Focaccio, Anna Violante, Pasquale Balestrieri, 
Bruno Golia, Pierfranco Scarpato, Pietro Paolo Elia, Stefano Lepore, Mariateresa 
Librera, Flavio Airoldi, Bruno Ricciardelli, Laboratory of Interventional Cardiology, Clinica 
Mediterranea, Naples, Italy, Laboratory of Interventional Cardiology, San Raffaele 
Hospital, Milan, Italy
Background: Myocardial injury after percutaneous coronary interventions (PCI) has
been recognized as a prognostically important event. Hermann et al. recently found in a
retrospective, non-randomized study that preprocedural statin therapy seems to be asso-
ciated with a reduction in the incidence of larger-sized, stenting-related myocardial infarc-
tions. Thus, we performed a prospective, randomized study to test this finding.
Methods: 470 patients scheduled for elective de novo PCI with stent implantation, not on
statins at the time of our observation, were randomly assigned to a pre-procedural (< 7
days before PCI) statin administration (Statin Group; n = 236) or to the Control Group (n
= 224). Incidence of periprocedural myocardial injury was assessed by analysis of creat-
ine kinase (CK-MB; upper limit of normal [ULN] 3.5 ng/mL) and cardiac troponin I (cTnI;
threshold 0.10 ng/mL) before 6, and 12, hours after the intervention.
Results. 34 patients (20 Statin group and 14 Control group) were missed because of
lack of CK-MB and/or cTnI data. The 2 groups were well matched for the most relevant
clinical, angiographic and procedural characteristics. IIbIIIa inhibitors were electively
administered in 57% of patients in the Control Group and 52% in the Statin Group (p=
0.31). Anatomic complication potentially responsible for myocardial injury (i.e. side
branch occlusion or compromise, prolonged slow-no flow) occurred in 7.5% in the Statin
Group versus 4.4% in the Control Group (p = 0.18). CK-MB peak was 5.5 ±13.3 ng/mL in
the Statin Group and 7.0 ±14.7 ng/mL in the Control Group (p = 0.026). cTnI peak was
0.85 ± 2.54 ng/mL in the Statin Group and 1.21 ± 2.61 in the Control Group (p = 0.029).
The incidence of CK-MB elevation >5x ULN was 5.4% in the Statin Group versus 11.7%
in the Control Group (OR = 0.43; 95% CI = 0.21-0.88; p = 0.025). The incidence of cTnI
elevation >5x was 21.2% in the Statin Group versus 31.3% in the Control Group (OR =
0.59; 95% CI = 0.38-0.90; p = 0.017).
Conclusions: This randomized study supports the findings that preprocedural statin
therapy is associated with a reduction in the incidence of periprocedural myocardial
injury.
1043-46 Vulnerable Plaque Can Be the Predominant Source of 
Serum Interleukin-6 but Not of Serum C-Reactive 
Protein in Patients With Acute Myocardial Infarction
Shuichiro Higo, Shinsuke Nanto, Masaaki Uematsu, Tomoki Ohara, Takakazu Morozumi, 
Jun-ichi Kotani, Masaaki Awata, Toshinari Onishi, Osamu Iida, Noriaki Ito, Seiki Nagata, 
Kansai Rosai Hospital, Amagasaki, Japan
Background: Although serum levels of interleukin (IL)-6 and C-reactive protein (CRP)
are elevated in patients with acute coronary syndrome, the origins of these inflammatory
markers remain uncertain.
Methods: We analyzed 19 patients with acute myocardial infarction who underwent
emergent percutaneous coronary intervention (PCI) using thrombus aspiration and distal
protection by PercuSurgeTM GuardWire system, which enabled intracoronary blood sam-
plings. Initial intracoronary aspiration, subsequent balloon angioplasty and/or stenting
under distal protection, and second aspiration were completed in all patients. Blood sam-
ples were obtained from the femoral artery (FA), the coronary artery before (Initial) and
after the balloon dilation of the culprit lesion under distal protection (Second). Serum lev-
els of IL-6 and high sensitive (hs)-CRP were measured.
Results: Shown in the table. Serum levels of IL-6 significantly increased after PCI (Sec-
ond), while hs-CRP remained unchanged throughout the procedure. Serum CRP levels
one day after the PCI markedly increased over any other samples (1.27±0.38 mg/dl,
p<0.0001). Thus, the mechanical disruption of the culprit lesion by PCI induced the ele-
vation of serum IL-6 levels, but had no influence on serum CRP levels.
Conclusion: Vulnerable plaque in patients with acute myocardial infarction can be the
predominant source of serum IL-6 but not of serum CRP.
1043-47 Evidence for Immediate Induced Percutaneous 
Coronary Intervention Matrix Metalloproteinase 2 
Variations in Peripheral Samples to Predict Target 
Vessel Revascularization After Nondrug-Eluting Stent 
Implantation
Camille Brasselet, Sophie Pérotin, Roselyne Garnotel, Antoine Lafont, Marie Métivier, 
Jacques Elaerts, Philippe Gillery, Damien Metz, CHU Robert Debre, Reims, France, 
American Memorial Hospital, Reims, France
Background and objectives:
Matrix metalloproteinases (MMPs) and inhibitors (TIMPs) play a pivotal role in healing
process by controlling the turn-over of the extracellular matrix. Recent studies have men-
tioned an increase of MMP after percutaneous coronary intervention (PCI), assessed in
the coronary sinus circulation, and its correlation with long term late loss. In search for
practical application, we investigated changes in the expression of MMPs and TIMPs
after PCI, through conventional sampling.
Material and Methods:
Adjusted Incremental Hospital Cost and LOS by Complication
Complication Incremental Cost Length of Stay (days)
Death $3,351 -0.9
Septicemia $21,610 9.1
Post-Operative Stroke $4,673 2.9
Acute Renal Failure $11,600 5.8
Vascular Complication $4,546 2.4
ARDS $15,667 4.6
CABG Surgery $25,388 4.9
FA Initial Second p value
IL-6 (pg/ml) 8.7±2.2 10.4±2.4 13.2±3.9* * p<0.01 vs FA
hs-CRP (mg/dl) 0.19±0.07 0.17±0.06 0.17±0.05 N.S.
